Cediranib information

Cediranib
Clinical data
Routes of; administration	Oral
ATC code	L01EK02 (WHO) ;
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
	IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;
CAS Number	288383-20-0 ;
PubChem CID	9933475;
IUPHAR/BPS	5664;
ChemSpider	8109103 ;
UNII	NQU9IPY4K9;
KEGG	D08881;
ChEMBL	ChEMBL491473 ;
CompTox Dashboard (EPA)	DTXSID10183035 ;
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.514 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc4cc3c(Oc2ccc1[nH]c(C)cc1c2F)ncnc3cc4OCCCN5CCCC5;
	InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 ; Key:XXJWYDDUDKYVKI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.^[1]^[2]^[3]

The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

^ Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Research. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
^ Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, et al. (March 2009). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group". European Journal of Cancer. 45 (5): 782–8. doi:10.1016/j.ejca.2008.10.022. PMID 19091548.
^ Nikolinakos P, Heymach JV (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". Journal of Thoracic Oncology. 3 (6 Suppl 2): S131-4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.

[pmid15899831-1] Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Research. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.

[pmid19091548-2] Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, et al. (March 2009). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group". European Journal of Cancer. 45 (5): 782–8. doi:10.1016/j.ejca.2008.10.022. PMID 19091548.

[pmid18520296-3] Nikolinakos P, Heymach JV (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". Journal of Thoracic Oncology. 3 (6 Suppl 2): S131-4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296.

Cediranib information

and 26 Related for: Cediranib information

Cediranib

Insulin

Cerebral edema

Amitriptyline

Cerebrolysin

Trastuzumab deruxtecan

Erythropoietin

Amivantamab

Faricimab

Testosterone

Filgrastim

HER2

Nintedanib

ATC code L01

Tyrosine kinase inhibitor

Nerve growth factor

Alectinib

Cetuximab

Adult neurogenesis

Dexamethasone

Bevacizumab

Imatinib

Dasatinib

Ponatinib

Epidermal growth factor

Ovarian cancer

Clinical data

Routes of administration	Oral
ATC code	L01EK02 (WHO)
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
CAS Number	288383-20-0^Y
PubChem CID	9933475
IUPHAR/BPS	5664
ChemSpider	8109103^N
UNII	NQU9IPY4K9
KEGG	D08881
ChEMBL	ChEMBL491473^N
CompTox Dashboard (EPA)	DTXSID10183035
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C₂₅H₂₇FN₄O₃
Molar mass	450.514 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COc4cc3c(Oc2ccc1[nH]c(C)cc1c2F)ncnc3cc4OCCCN5CCCC5
InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3^N Key:XXJWYDDUDKYVKI-UHFFFAOYSA-N^N
^NY (what is this?) (verify)